Archived 35: Summary of NACI statement of March 17, 2022:  Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age

Notice to reader

Download in PDF format
(807 KB, 4 pages)

Organization: Public Health Agency of Canada

Published: 2022-03-17

Published: March 17, 2022

On this page

Overview

NACI recommends that:

  • A complete series with an mRNA COVID-19 vaccine should be offered to children in the authorized age groups without contraindications to the vaccine, with a dosing interval of at least 8 weeks between the first and second dose. (Strong NACI Recommendation).

For children 6 to 11 years of age, for whom the Moderna Spikevax (50 mcg) COVID-19 vaccine primary series is now authorized:

  • Moderna Spikevax (50 mcg dose) may be offered as an alternative to Pfizer-BioNTech Comirnaty (10 mcg dose), however the use of Pfizer-BioNTech Comirnaty (10 mcg dose) is preferred to Moderna Spikevax (50 mcg dose) to start or continue the primary vaccine series.

For the full statement, including recommendations for those children with immune compromise, please see NACI recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age.

For more information on NACI’s recommendations on the use of COVID-19 vaccines, please refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.

What you need to know

For the full statement, please see NACI statement: Recommendations on the use of the Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age.

For more information on NACI’s recommendations on the use of COVID-19 vaccines, please refer to the COVID-19 vaccine chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.

Quotes

“NACI continues to recommend that children should be vaccinated for protection from COVID-19. The committee has reviewed the available evidence on the newly authorized use of the Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age. Clinical trials have shown that this vaccine has a good safety profile and has good efficacy to protect children from COVID-19. Pfizer-BioNTech Comirnaty is preferred for the primary series in children 5 to 11 years, consistent with recommendations for those who are 12 to 29 years old and based upon its safety profile, but Moderna Spikevax is an option for children 6 to11 years old that may be used. NACI will continue to monitor the real-world use of this vaccine and provide updated recommendations as appropriate.”

Dr. Robyn Harrison, NACI Vice-chair

“A COVID-19 vaccine primary series for children following the recommended 8 week interval between doses continues to be important as we move into the next stage of the pandemic. I am pleased to see COVID-19 vaccines being made available to different age groups, and I thank NACI for continuing to provide expert advice about which vaccine options are best suited for certain populations.”

Dr. Theresa Tam, Chief Public Health Officer
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: